breast cancer
Conditions
Interventions
Lentinula edodes mycelia
placebo
Sponsors
Japan Society for Cancer Chemotherapy
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Patients with histologically confirmed breast cancer 2.Patients who are scheduled to initiate treatment with a drip infusion every 3 week cycle (FEC, EC, AC, CAF) among chemotherapy including anthracycline antitumor drugs 3.Patients with sufficient function of main organs to undergo chemotherapy 4.Patient with a performance status (ECOG scale) of 0 - 1 5.Patients with life expectancy of at least 3 month from the date of enrollment 6.Patients who are aged 20 years or older at the time of obtaining informed consent 7.Female patients 8.Patients who are able to maintain sufficient oral intake 9.Patients who are able to submit written informed consent for participation in this study
Exclusion criteria
Exclusion criteria: 1.Patients who are pregnant or may be pregnant 2.Patients who are nursing 3.Patients who received previous treatments other than surgery (such as radiation therapy, chemotherapy and hormone therapy) in the last 4 weeks after study enrollment. 4.Patients who started taking the following new healthy foods in the past 2 weeks after enrollment in this study. Agaricus, Tturmeric, Shark cartilage, Propolis, Bracket fungus, Coenzyme Q10, Aojiru (Green juice), Chlorella, Phellinus linteus, Fucoidan, Royal jelly, DHA, Aloe, PC-SPEC, Saw palmetto, Ganoderma lucidum, Selenium, b-carotene, Isoflavone, Garlic, Black vinegar, Ginkgo leaf extract, Lactobacillus preparation, etc. 5.Patients who are considered ineligible for participation in this study based on decision of a responsible investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| QOL | — |
Secondary
| Measure | Time frame |
|---|---|
| immuno parameter adverse event | — |
Countries
Japan
Outcome results
None listed